Featured Publications
Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
Prunas O, Warren JL, Crawford FW, Gazit S, Patalon T, Weinberger DM, Pitzer VE. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. Science 2022, 375: eabl4292. PMID: 35084937, PMCID: PMC9261115, DOI: 10.1126/science.abl4292.Peer-Reviewed Original ResearchConceptsVaccine effectivenessSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Effectiveness of vaccinesEffectiveness of vaccinationTotal vaccine effectivenessSARS-CoV-2Household contactsSecond doseCoronavirus 2Household transmissionDelta variantDay 10VaccinationBNT162b2COVID-19InfectionChain binomial modelVaccineDoseImmunity
2022
Detection of pneumococcus during hospitalization for SARS-CoV-2
Stahlfeld A, Glick L, Ott I, Craft S, Yolda-Carr D, Harden C, Nakahata M, Farhadian S, Grant L, Alexander-Parrish R, Arguedas A, Gessner B, Weinberger D, Wyllie A. Detection of pneumococcus during hospitalization for SARS-CoV-2. FEMS Microbes 2022, 3: xtac026. PMID: 37332510, PMCID: PMC10117745, DOI: 10.1093/femsmc/xtac026.Peer-Reviewed Original ResearchLower respiratory tract infectionsUrine antigen detectionPneumococcal lower respiratory tract infectionSARS-CoV-2COVID-19 severityDetection of pneumococciRespiratory infectionsSerious COVID-19 outcomesSARS-CoV-2 coinfectionYale-New Haven HospitalViral respiratory infectionsCOVID-19 inpatientsModerate COVID-19Respiratory tract infectionsSevere pneumococcal infectionRT-qPCRRole of coinfectionCOVID-19 outcomesEarly pandemic periodCOVID-19ICU stayPneumococcal coinfectionPneumococcal infectionTract infectionsMedian ageOdds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine
Patalon T, Gazit S, Pitzer VE, Prunas O, Warren JL, Weinberger DM. Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine. JAMA Internal Medicine 2022, 182: 179-184. PMID: 34846533, PMCID: PMC8634151, DOI: 10.1001/jamainternmed.2021.7382.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Maccabi Healthcare ServicesBooster doseBNT162b2 vaccineMRNA vaccinesPositive SARS-CoV-2 polymerase chain reaction testSARS-CoV-2 polymerase chain reaction testPreliminary retrospective case–control studyRetrospective case-control studyPositive PCR test resultsBNT162b2 mRNA vaccineVaccine-derived protectionTest-negative designDuration of immunityCase-control studyPolymerase chain reaction testEstimated odds ratioHealthcare servicesCase-control analysisPCR test resultsPositive test resultsChain reaction testCase-control designTesting PositiveOdds ratio
2021
Estimation of the Timing and Intensity of Reemergence of Respiratory Syncytial Virus Following the COVID-19 Pandemic in the US
Zheng Z, Pitzer VE, Shapiro ED, Bont LJ, Weinberger DM. Estimation of the Timing and Intensity of Reemergence of Respiratory Syncytial Virus Following the COVID-19 Pandemic in the US. JAMA Network Open 2021, 4: e2141779. PMID: 34913973, PMCID: PMC8678706, DOI: 10.1001/jamanetworkopen.2021.41779.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusRSV epidemicsMathematical modelRSV hospitalizationRSV seasonSyncytial virusSummer epidemicsRSV lower respiratory tract infectionLower respiratory tract infectionsCOVID-19 pandemicLarge RSV outbreaksMaternal-derived immunityRespiratory tract infectionsChildren 1 yearYears of ageSARS-CoV-2Simulation modeling studyProphylaxis administrationRSV circulationRSV infectionRSV outbreaksSecondary outcomesTract infectionsPrimary outcomeLeading cause